ACADIA Pharmaceuticals (ACAD) : During the past 4 weeks, traders have been relatively bearish on ACADIA Pharmaceuticals (ACAD), hence the stock is down -5.91% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -14.08% relative to the S&P 500. The 4-week change in the price of the stock is -4.94% and the stock has fallen -14.03% in the past 1 week.
The stock has recorded a 20-day Moving Average of 11.14% and the 50-Day Moving Average is 11.54%. ACADIA Pharmaceuticals (NASDAQ:ACAD): On Fridays trading session , Opening price of the stock was $31.71 with an intraday high of $31.8. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $31.27. However, the stock managed to close at $31.37, a loss of 1.57% for the day. On the previous day, the stock had closed at $31.87. The total traded volume of the day was 1,127,409 shares.
The company Insiders own 22.42% of ACADIA Pharmaceuticals shares according to the proxy statements. Institutional Investors own 97.74% of ACADIA Pharmaceuticals shares. Also, Bank of America downgrades its view on ACADIA Pharmaceuticals (NASDAQ:ACAD) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Earlier, the shares had a rating of Buy. The rating by the firm was issued on June 22, 2016.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.